GenomOncology Receives $250K in Funding from JumpStart

GenomOncology, a Cleveland, OH-based company developing technology to automate the analysis of sequenced genetic information, has received $250k in funding from JumpStart.

The company, which is continuing to raise capital in this current round, plans to use the funding to develop a commercialization strategy, build out the management team and secure its first commercial contracts.

Led by founder and CEO Manuel J. Glynias, GenomOncology provides proprietary software and analytical tools that can interactively analyze and interpret sequenced genomic data. The technology is designed to detect and analyze gene mutations, a hallmark of the presence of cancer, within the sequenced genomes.



Join the discussion